Lytix Biopharma ASA
LYTIX.XOSL
Lytix Biopharma ASA is a clinical-stage biotechnology company focused on developing cancer immunotherapies that activate and strengthen the patient’s immune response against tumors. Its principal product candidate, ruxotemitide, is an oncolytic molecule designed for intratumoral administration and is being developed for conditions including melanoma, basal cell carcinoma, and advanced soft-tissue sarcoma. The company is also evaluating its technology in combination-treatment settings, including studies pairing ruxotemitide with pembrolizumab. Lytix Biopharma ASA operates within the pharmaceutical biotechnology sector, concentrating on research, clinical development, and the potential commercialization or licensing of therapies for cancer and related medical applications. Headquartered in Oslo, Norway, the company represents the clinical-development segment of the healthcare market, where specialized biotechnology firms advance targeted therapeutic platforms toward regulatory approval and potential use by hospitals, oncology specialists, and pharmaceutical partners. Its activities span drug development, clinical research, intellectual-property management, and collaboration across the international oncology ecosystem.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 0.00
▼ -100.0% YoY
Net Income (TTM)
-NOK 95M
▲ +36.4% YoY
Op. Margin
–
ROIC
-57.98%
▲ +35.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 87M
▲ +15.0% YoY
Op. Cash Flow (TTM)
-NOK 87M
▲ +15.0% YoY
Net Debt
-NOK 69M
Net Cash Position
Cash & Equiv.
NOK 72M
Continue Research
Peers
Biotechnology · Pick stocks to compare with LYTIX.XOSL
Lytix Biopharma ASA (LYTIX.XOSL) in three numbers
Questions about Lytix Biopharma ASA
Is Lytix Biopharma ASA a high-quality business?
Lytix Biopharma ASA scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$69M, and its weakest is return on capital at -58.0%. The Quality tab shows every check against its target.
Does Lytix Biopharma ASA (LYTIX.XOSL) pay a dividend?
No. Lytix Biopharma ASA (LYTIX.XOSL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 16 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LYTIX.XOSL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.